{"contentid": 488215, "importid": NaN, "name": "Astellas puts gene therapy at heart of R&D strategy", "introduction": "Japanese company Astellas has become the latest drugmaker to make genetic regulation one of the primary focuses of its research and development (R&D) strategy.", "content": "<p>Japanese company Astellas (TYO: 4503) has become the latest drugmaker to make genetic regulation one of the primary focuses of its research and development (R&amp;D) strategy.</p>\n<p>The group has announced plans to further integrate its wholly-owned subsidiary, Audentes Therapeutics, and establish Astellas Gene Therapies within the organization.</p>\n<p>This will involve further advancing Astellas&rsquo; activities in R&amp;D, manufacturing and commercialization of the associated programs with a foundation in adeno-associated virus (AAV)-based gene therapy.</p>\n<p>Astellas claims that the new center of excellence will enable it to achieve more effective and efficient operations, with a high-quality, safety and compliance standard.</p>\n<p>The center of excellence will operate through three divisions specializing in research including technical operations, medical and development, and future commercialization of gene therapy programs.</p>\n<p>There will be a focus on the programs for neuromuscular diseases brought by Audentes including its lead candidate AT132 for X-linked myotubular myopathy and AT845 for Pompe disease, in addition to advancing additional Astellas&rsquo; gene therapy programs toward clinical investigation.</p>\n<p>Kenji Yasukawa, president and chief executive, Astellas, said: &ldquo;The field of gene therapy has made significant strides to date, and we believe the future holds even greater opportunity to bring new treatments to a wide range of diseases for patients in need.</p>\n<p>&ldquo;With Astellas Gene Therapies as a Center of Excellence, we can continue to deepen our knowledge in this ever-evolving space with the expertise and talent from within Audentes to lead us to the forefront of creating next-generation treatments.&rdquo;</p>\n<p>In the future, instead of alternating between the Astellas and Audentes umbrella brands by program, the company will come together under one banner as Astellas Gene Therapies to advance its efforts in the field.</p>\n<p>&nbsp;</p>", "date": "2021-03-31 13:20:00", "meta_title": NaN, "meta_keywords": "Astellas, gene, therapy, strategy, research, development, programs, company, Audentes, heart, puts, drugmaker, genetic, regulation, primary, focuses, lates", "meta_description": "Japanese company Astellas has become the latest drugmaker to make genetic regulation one of the primary focuses of its research and development (R&D) strategy.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-31 13:16:25", "updated": "2021-03-31 13:54:22", "access": NaN, "url": "https://www.thepharmaletter.com/article/astellas-puts-gene-therapy-at-heart-of-r-d-strategy", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "astellas-location-big.jpg", "image2id": "astellas-location-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Cell and Gene Therapy, Genetics, Genomics", "topic_tag": "Management, Research", "geography_tag": "Japan", "company_tag": "Astellas, Audentes Therapeutics", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-31 13:20:00"}